The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | CD58 aberrations correlate with poor response to axi-cel in LBCL
David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the findings of a study investigating tumor specific factors associated with inherent or acquired resistance to axicabtagene ciloleucel (axi-cel) CAR-T cell therapy in large B cell lymphoma (LBCL). The study analyzed tumor DNA, from blood or tumor biopsies, in patients treated with axi-cel. The study found that mutations in, and loss of expression of, LFA-3 (CD58) correlated with lack of response or poor response longevity to axi-cel treatment. This was shown to be due to subsequent loss of CD2 signaling, which has a costimulatory role in T-cells. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
